discuss with doctor if severe Week 1316: Maintenance Dose (9mg or continuing to 12mg) For 9mg group (maintenance): Side effects stabilize Nausea decreases (2025% still experiencing) Dysesthesia: 8.8% incidence (mild) Body adapting well For 12mg group (final increase): GI effects may temporarily worsen (4045% nausea) Dysesthesia peaks (20.9% incidence) This is the "make or break" dose highest efficacy, highest side effects Duration: 12 weeks adjustment period Week 17+: Long-Term Maintenance Side effects: Nausea: Decreases to 1525% (down from 4045%) Diarrhea: Improves to 1020% Dysesthesia: Stable at 8.820.9% (doesn't worsen) Most people feel "normal" except for reduced appetite Key point: Side effects are WORST during dose escalation (weeks 116)
Based on the current Phase 3 timeline, retatrutide is not expected to receive FDA approval before late 2027
Cutting Calories Too Aggressively on Top of the Compound Retatrutide already creates a significant caloric deficit through appetite suppression
Blonde L, Belousova L, Fainberg U, et al
But what happens when you stop
Asia-Pacific is the fastest-growing regional GLP-1 drug market at 22.6% CAGR , driven by rapidly rising obesity prevalence China now reports 18.6% adult obesity prevalence up from 7.1% in 2000 combined with expanding private health insurance and regulatory approvals
